Mechel Reports Joint Project With Russia's Federal Labor

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Mechel Reports Joint Project With Russia's Federal Labor and Employment Service

MOSCOW, April 10, 2014 (GLOBE NEWSWIRE) -- Mechel OAO (NYSE: MTL ) , one of the leading Russian mining and metals companies, announces the launch of a pilot project on stepping up the efficiency of measures for improvement of labor conditions at the Group's enterprises.

The project will be implemented jointly with Russia's Federal Labor and Employment Service as part of that agency's new activity model – Open Labor Inspection, which is due to be set up in the Russian Federation by 2018.

Mechel Group was chosen for implementing this project as one of Russia's major employers, with activities involving diversified industrial facilities.

As part of the project, a monitoring will be held in 2014, analyzing work conditions and labor safety systems in 21 of Mechel's facilities. As a result, a comprehensive plan for improving work conditions will be designed, taking into account the newest amendments to Russian labor law.

"We are grateful to Russia's Labor and Employment Service for choosing Mechel as one of Russia's major employers for testing their new project. Our company consistently implements promotion programs for our personnel, educational and social programs. We invest a lot of effort into creating comfortable work conditions for our employees and strictly comply with all labor law requirements. Implementing this project will enable us to improve work conditions and efficiency of our employees' labor safety activities," Mechel OAO's Vice-President for Human Resources and Social Policy Elena Selivanova commented.

Mechel is an international mining and steel company which employs over 80,000 people. Its products are marketed in Europe, Asia, North and South America, Africa. Mechel unites producers of coal, iron ore concentrate, steel, rolled products, ferroalloys, heat and electric power. All of its enterprises work in a single production chain, from raw materials to high value-added products.

Some of the information in this press release may contain projections or other forward-looking statements regarding future events or the future financial performance of Mechel, as defined in the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We wish to caution you that these statements are only predictions and that actual events or results may differ materially. We do not intend to update these statements. We refer you to the documents Mechel files from time to time with the U.S. Securities and Exchange Commission, including our Form 20-F. These documents contain and identify important factors, including those contained in the section captioned "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in our Form 20-F, that could cause the actual results to differ materially from those contained in our projections or forward-looking statements, including, among others, the achievement of anticipated levels of profitability, growth, cost and synergy of our recent acquisitions, the impact of competitive pricing, the ability to obtain necessary regulatory approvals and licenses, the impact of developments in the Russian economic, political and legal environment, volatility in stock markets or in the price of our shares or ADRs, financial risk management and the impact of general business and global economic conditions.

Mechel OAO Ekaterina Videman Tel: + 7 495 221 88 88

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 938

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 240

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 188

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 150

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 462

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 289

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 309

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 261

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Sonic Partners with Obsessed Garage for Home Garage Solutions

Updated Category News Views 147

Sonic Teams Up with Obsessed Garage to Transform Home Garages Sonic, a front-runner in delivering high-quality tool solutions and equipment, has recently announced an exciting partnership with Obsessed Garage. This collaboration aims to cater to home garage enthusiasts who demand tools and storage solutions that match the quality standards utilized by professionals in the...

Continue Reading
Investors of Sun Communities, Inc. Urged to Act Before Deadline

Updated Category News Views 167

Important Update for Sun Communities, Inc. Investors There is a significant call to action for investors of Sun Communities, Inc. as a class action lawsuit has been filed against the company, urging those affected to act promptly. This is a crucial moment for investors who purchased securities from the company during a specific period. Legal representation is being...

Continue Reading
XOMA Stock Reaches New Heights: Key Developments and Insights

Updated Category News Views 67

XOMA Stock Performance Overview XOMA Ltd's stock has recently made headlines by reaching a remarkable 52-week high, with shares trading at an impressive $30.49. This achievement not only signifies a significant milestone for the company but also highlights a robust year-over-year growth that can't be overlooked. Investors have observed a substantial increase of 73.82% in...

Continue Reading
Evolv Technologies Faces Turmoil with Executive Departures

Updated Category News Views 230

Evolv Technologies Faces Turmoil with Executive Departures Evolv Technologies Holdings (NASDAQ: EVLV) is navigating turbulent times following the resignation of its Chief Financial Officer, Mark Donohue. His departure comes amid serious allegations of improper revenue recognition practices that have raised questions about the company's integrity and financial health....

Continue Reading
Editas Medicine: Financial Insights and Market Strategies Revealed

Updated Category News Views 56

Editas Medicine Maintains Price Target Amidst Financial Developments Recently, Leerink Partners reaffirmed a Market Perform rating for Editas Medicine (NASDAQ: EDIT), keeping a price target steady at $8.00. This decision comes closely after the company announced a substantial financing agreement with DRI Healthcare Trust. Under this agreement, Editas is set to receive an...

Continue Reading